Zacks: Analysts Expect Trillium Therapeutics Inc (NASDAQ:TRIL) Will Post Earnings of -$0.22 Per Share

Brokerages expect that Trillium Therapeutics Inc (NASDAQ:TRIL) (TSE:TR) will announce earnings per share (EPS) of ($0.22) for the current quarter, according to Zacks. Zero analysts have made estimates for Trillium Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.24) and the highest estimate coming in at ($0.20). Trillium Therapeutics posted earnings of ($0.42) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 47.6%. The firm is scheduled to issue its next earnings report on Monday, March 9th.

According to Zacks, analysts expect that Trillium Therapeutics will report full year earnings of ($1.24) per share for the current financial year, with EPS estimates ranging from ($1.31) to ($1.19). For the next year, analysts expect that the company will report earnings of ($0.66) per share, with EPS estimates ranging from ($0.74) to ($0.57). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover Trillium Therapeutics.

Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) last announced its earnings results on Thursday, November 14th. The biotechnology company reported ($0.26) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.33) by $0.07. The firm had revenue of $0.10 million for the quarter.

Several equities research analysts recently commented on TRIL shares. ValuEngine cut Trillium Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, January 10th. HC Wainwright reissued a “hold” rating on shares of Trillium Therapeutics in a report on Monday, November 18th. Cowen reissued a “buy” rating on shares of Trillium Therapeutics in a report on Tuesday, January 7th. Finally, Zacks Investment Research cut Trillium Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, December 25th.

NASDAQ:TRIL traded up $0.29 during midday trading on Friday, hitting $4.51. 11,408,809 shares of the stock were exchanged, compared to its average volume of 8,964,649. Trillium Therapeutics has a one year low of $0.24 and a one year high of $4.86. The company has a market capitalization of $118.32 million, a price-to-earnings ratio of -3.22 and a beta of 2.89. The business has a 50-day moving average price of $1.48 and a two-hundred day moving average price of $0.61.

An institutional investor recently raised its position in Trillium Therapeutics stock. Morgan Stanley boosted its holdings in Trillium Therapeutics Inc (NASDAQ:TRIL) (TSE:TR) by 35.8% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,045,698 shares of the biotechnology company’s stock after buying an additional 275,800 shares during the quarter. Morgan Stanley owned 3.73% of Trillium Therapeutics worth $343,000 as of its most recent SEC filing. 24.34% of the stock is owned by hedge funds and other institutional investors.

Trillium Therapeutics Company Profile

Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trials for advanced hematologic malignancies, and solid tumors and mycosis fungoides.

Read More: Shanghai Stock Exchange Composite Index

Get a free copy of the Zacks research report on Trillium Therapeutics (TRIL)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with's FREE daily email newsletter.